NCT04934007 Bilateral Lateral OFC rTMS in Obsessive Compulsive Disorder
| NCT ID | NCT04934007 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Henri Laborit |
| Condition | Obsessive-Compulsive Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 136 participants |
| Start Date | 2021-09-06 |
| Primary Completion | 2027-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 136 participants in total. It began in 2021-09-06 with a primary completion date of 2027-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
According to the literature the lateral part of the Orbito Frontal Cortex (lOFC) is a relevant bilateral target for repetitive Trans-cranial Magnetic Stimulation (rTMS) in Obsessive Compulsive Disorder (OCD). Both hemispheres are concerned in terms of target.
Eligibility Criteria
Inclusion Criteria: * Age: Participants will be both males and females, 18-65 years of age included. * diagnosis of OCD * all the patients must have failed to respond to at least two different pharmacological treatment used for at least 6 weeks * Affiliation to a social security system (recipient or assignee), * Signed written inform consent form Exclusion Criteria: * The exclusion criteria are a diagnosis of another psychiatric disorder (except for anxious disorders), a diagnosis of a significant active medical illness, pregnancy or other neurological illness * In accordance with the safety criteria for rTMS, patients with a history of seizure or bearing pacemakers, mobile metal implants, implanted medical pumps, or metal clips placed inside the skull will also be excluded * The patients won't be allowed to change their medication during the trial. The treatment must be stable at least 3 week before day 0. * Female subject who is pregnant, or of child-bearing age, sexually active and not using reliable contraception or who is nursing, * Patient under curators * Patient hospitalized under duress * Patient unable to give his or hers informed consent
Contact & Investigator
Ghina Harika-Germaneau
STUDY DIRECTOR
Centre Hospitalier Henri Laborit
Frequently Asked Questions
Who can join the NCT04934007 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Obsessive-Compulsive Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04934007 currently recruiting?
Yes, NCT04934007 is actively recruiting participants. Contact the research team at ghina.harika.germaneau@ch-poitiers.fr for enrollment information.
Where is the NCT04934007 trial being conducted?
This trial is being conducted at Paris, France, Poitiers, France.
Who is sponsoring the NCT04934007 clinical trial?
NCT04934007 is sponsored by Centre Hospitalier Henri Laborit. The principal investigator is Ghina Harika-Germaneau at Centre Hospitalier Henri Laborit. The trial plans to enroll 136 participants.